Literature DB >> 16596248

Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.

María-Encarnación Fernández-Contreras1, Sandra Sánchez-Prudencio, José-Javier Sánchez-Hernández, María-Luisa García de Paredes, Javier P Gisbert, Pedro Roda-Navarro, Carlos Gamallo.   

Abstract

Several variables associated to thymidylate synthase (TS), the biological target of 5-fluorouracil (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients. The level of protein expression and the number of variable tandem-repeats of a 28-bp sequence within the gene promoter have been proposed as predictive and/or prognostic factors with variable agreement, while consensus seems to be achieved with respect to the value of a single nucleotide polymorphism (SNP) described within this same region. More recently, an association between TS expression pattern and survival has been disclosed. Paraffin-embedded sections from 140 CRC patients were analyzed by immuno-histochemistry (Mab TS106) for TS levels and expression pattern. Also, VNTR and SNP were determined by polymerase-chain reaction (PCR) and restriction-length-fragment polymorphism (RFLP) in 123 and 112 patients, respectively. Cytoplasmic expression pattern tended to be associated to C SNP (p=0.06). Low TS expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with 5FU. Accordingly, patients having at least two favourable or unfavourable variables were classified respectively as 'low risk' and 'high risk', the former showing significantly longer PFS (p=0.0299). The possibility for designing a selection method for subsequent therapies is suggested on the basis of a probable combined effect of the above mentioned parameters but further studies in larger populations are needed to confirm these results.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596248

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.

Authors:  A Fariña-Sarasqueta; M J E M Gosens; E Moerland; I van Lijnschoten; V E P P Lemmens; G D Slooter; H J T Rutten; Adriaan J C van den Brule
Journal:  Cell Oncol (Dordr)       Date:  2011-06-01       Impact factor: 6.730

Review 2.  Multidisciplinary management in rectal cancer.

Authors:  Asunción Hervás Morón; María Luisa García de Paredes; Eduardo Lobo Martínez
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

Review 3.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas.

Authors:  Mads Aarhus; Ove Bruland; Geir Bredholt; Helle Lybaek; Eystein S Husebye; Bård K Krossnes; Christian Vedeler; Knut Wester; Morten Lund-Johansen; Per M Knappskog
Journal:  J Neurooncol       Date:  2008-03-26       Impact factor: 4.130

5.  An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens.

Authors:  Ying-Chao Wang; Hui-Ping Xue; Zhen-Hua Wang; Jing-Yuan Fang
Journal:  Mol Biol Rep       Date:  2013-05-05       Impact factor: 2.316

6.  Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy.

Authors:  Wen-Juan Li; Hua Jiang; Xin-Jian Fang; Hong-Ling Ye; Ming-Huan Liu; Yan-Wen Liu; Qian Chen; Li Zhang; Jin-Yu Zhang; Chun-Luan Yuan; Qiu-Yun Zhang
Journal:  Oncol Lett       Date:  2013-02-04       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.